291 results on '"Alvarez, Ricardo H."'
Search Results
2. PS2-4 Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expression
3. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
4. HER2-positive metastatic breast cancer: second-line treatment
5. Drug-Resistant TNBC: The Search for Novel Therapeutic Approaches
6. Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer
7. Data from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
8. Supplementary Figure 1 from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
9. Supplementary Figure Legend from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
10. HER2-Positive Metastatic Breast Cancer: Second-Line Treatment
11. Supplemental Tables 1 and 2 from Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors
12. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer
13. Identification of frequent somatic mutations in inflammatory breast cancer
14. Central Nervous System Involvement in Adult Acute Lymphocytic Leukemia
15. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis
16. Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs
17. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation
18. Handbook of HER2-Targeted Agents in Breast Cancer
19. Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma
20. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis
21. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
22. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
23. Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design
24. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer
25. Handbook of HER2-targeted agents in breast cancer
26. Novel targeted agents for the treatment of advanced breast cancer
27. Abstract P1-18-30: Neoadjuvant aromatase inhibitor and pertuzumab and trastuzumab (NEOADAPT) up to one year for HR+HER2+ breast cancer: Results from a prematurely closed de-escalation study
28. Palbociclib in Patients With Pancreatic and Biliary Cancer WithCDKN2AAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study
29. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer: Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099
30. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
31. Supplementary_Table_2A_1 – Supplemental material for Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer
32. the Role of Src in Solid and Hematologic Malignancies: Development of new-generation Src inhibitors
33. Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
34. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis
35. Evaluation of an NCCN guideline-based weight management pathway on weight loss in female breast cancer patients.
36. Evaluation of cancer patients’ perspectives on weight management counseling at a comprehensive cancer center.
37. Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with FLT-3 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
38. Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported KRAS, NRAS, BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
39. Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reportedKRAS, NRAS, BRAFmutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
40. Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) withFLT-3alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
41. Mutational landscape of ovarian cancers (OC) identified by prospective clinical sequencing in a nationwide cancer network.
42. Effects on histologic subgroup, race, and BMI in 2,110 breast cancer patient: Results from single institution in Georgia.
43. Mutational landscape of endometrial cancer identified by prospective clinical sequencing in a nationwide cancer network.
44. Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
45. Mutational landscape of cervical cancer identified by prospective clinical sequencing in a nationwide cancer network.
46. Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients.
47. Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
48. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer
49. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center
50. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.